

Drugs and pharmaceuticals industry—Cont.**Research and development—Cont.**

- Clinical/basic/market research, distinguishing, future prospects, etc., 3:18, 28, 55, 62-4, 66; 6:34-5, 44-6; 7:11-2; 8:8-9; 10:41; 11:14; 12:13, 30, 40, 66, 75; 13:10, 26, 31, 46; 14:8, 15; 15:37-8, 54
- Compulsory licensing, effect, 6:45; 8:57, 61, 67; 12:5, 32, 39; 14:31-2, 63-4
- Royal College of Physicians and Surgeons, training programs developing, 15:54
- See also Drugs and pharmaceuticals industry—Montreal, Quebec
- Current state in Canada, no significant activity, 11:10; 12:29; 14:75-6; 15:48
- Development costs, new product, \$100 million, 8:51; 10:39, 41; 12:9-10, 12, 21, 67
- Haddad comment, 12:9, 67
- Economies of scale, 13:27
- Employment, Bill C-22 stimulating, 3,000 jobs, estimate, 1:16-8, 22, 33-4, 45; 3:10, 31-2, 45-6, 55-7, 65; 5:43; 6:25-6, 61; 7:6; 9:45-6, 50-1; 10:7; 11:9, 40, 56; 12:6, 66; 14:68, 73-5; 15:32, 55, 87
- Atlantic Canada, no gains, 9:26
- Information, requesting, 3:57
- National Health and Welfare Department, Health Protection Branch, new regulations, effect, 14:68-9
- Puerto Rico, greater growth, 15:55, 59, 74
- Funding, public, necessity, 6:27
- Gross National Product, 2.5% benchmark, Mulroney pledge, 12:36; 15:47-8
- Health care costs, lowering, 9:17
- Income Tax Act, multinationals encouraging, 3:54, 64; 6:29; 15:53
- Intramural/extramural research, defining, 14:10
- "Me too" emphasis, thalidomide mix-up example, etc., 15:73-5
- Multinationals, reliance, questioning, 14:31
- See also Drugs and pharmaceuticals industry—Research and development, Income Tax Act
- Project mobility, 15:41-2
- Sales ratio, 16:18-9
- Spending, international comparison, 14:8, 18
- Universities, hospitals, share, 1:34; 6:26-7; 11:12
- World product mandate, need, 10:42; 12:12; 14:76
- See also Brand name drugs—Research and development record
- See also Diseases—Infectious, Sexually transmitted; Drugs and pharmaceuticals industry—Montreal—Profits
- Return on investment, 3:37
- Sales, total, 1985, 1:12
- Self-insurance, vaccines, 1:27
- Stimulating, international comparison, Japan, etc., 3:34-5, 54
- Technology transfer, need, 14:8, 18
- Transfer pricing issue, fine chemicals, etc., 1:37-9; 3:6, 8, 12, 15, 53; 5:14-5; 15:88
- Information, requesting, 3:12, 52-3
- National Revenue Department lawsuits, 3:8
- World class, establishing, 3:7-8, 11; 6:51-2; 7:6, 8; 8:58, 63
- Organization for Economic Co-operation and Development study, 7:6, 12
- See also Diseases—Sexually transmitted; Generic drugs—Industry

Drury, Victor (Kidney Foundation of Canada)
Patent Act (amdt.)(Bill C-22), 13:3, 5, 14-6

Dyck, Jake (Canadian Medical Association)
Patent Act (amdt.)(Bill C-22), 13:3, 16-7

Eastman, Dr. Harry C. (Individual presentation)

Patent Act (amdt.)(Bill C-22), 5:3, 10-33

References see Drug Prices Review Board—Regulatory powers, Regulatory capture; Patent Act (amdt.)(Bill C-22)—References

Eastman report

Provinces, favouring, 1:37

See also Brand name drugs; Canadian Society for Clinical Investigation; Drug patents; Drugs and pharmaceuticals—Costs/prices, Legislation—Purchasing from abroad; Drugs and pharmaceuticals industry—Profits, Research and development; Generic drugs—Royalty payments; Patent Act (amdt.)(Bill C-22)—References, Alternatives

Economic Council of Canada

Compulsory licensing position, 1971, 15:97

Legislation, Bill C-22, no position taken, 14:73

See also Drug patents—Returns to inventor

Economies of scale see Drugs and pharmaceuticals industry—Research and development

Economist, The see Drugs and pharmaceuticals industry—Research and development, Centralization

Education see Brand name drugs—Research and development record, Expenditures; Diseases—Infectious; Drugs and pharmaceuticals industry

Elston, Hon. Murray see Ontario

Employment see Apotex—Sales; Bio-medical research; Biotechnology industry; Disabled and handicapped; Drugs and pharmaceuticals industry—Research and development

Epp, Hon. Jake see Health care—Canada Health Act

Erola, Hon. Judy see Pharmaceutical Manufacturers Association of Canada—Lobbying pressure

Exclusivity periods see Brand name drugs; Generic drugs—Manufactured in Canada

Farmers see Saskatchewan—Grain farmers

Federal Superannuates National Association

Background, 14:59-60

See also Witnesses

Fédération de l'âge d'or du Québec see Quebec Federation of Senior Citizens

Fermentation see Biotechnology industry—Research and development, Recombinant DNA research

Fine chemicals see Brand name drugs—Exclusivity period from imports; Drugs and pharmaceuticals industry

Fisk, George (Patent and Trademark Institute)
Patent Act (amdt.)(Bill C-22), 6:3, 7-10, 12-8

Fontaine, Gabriel (PC—Lévis)

Multiple Sclerosis Society of Ottawa-Carleton, 8:16

Paris Convention, 8:28

Patent Act (amdt.)(Bill C-22), 8:5, 16, 28

Food and Drug Act, 3:63

Ford Motor Company of Canada Limited see Drug plans—Generic

Foreign investment

Take-overs see Ayerst Laboratories; Merck Frosst Canada Inc.